Pfizer, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Albert Bourla
- Full Time Employees
- 75,000
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 66 Hudson Boulevard East New York NY United States 10001-2192
- IPO Date
- Jan 17, 1944
- CIK
- 0000078003
- Website
- pfizer.com
- Similar Companies
- Business
- Pfizer Inc. (NYSE: PFE) develops, manufactures, and markets biopharmaceutical products worldwide, focusing on oncology, vaccines, internal medicine, inflammation and immunology, and rare diseases. The company offers a broad portfolio including oncology drugs such as Ibrance (palbociclib), Xtandi (enzalutamide), Padcev (enfortumab vedotin), Elrexfio (elranatamab), Bosulif (bosutinib), Braftovi (encorafenib), Lorbrena (lorlatinib), Talzenna (talazoparib), and Tivdak (tisotumab vedotin); vaccines like Comirnaty (COVID-19 mRNA vaccine), Prevnar 13/20 (pneumococcal conjugate vaccines), Abrysvo (RSV vaccine), and Penbraya (meningococcal vaccine); cardiovascular and metabolic treatments including Eliquis (apixaban), Vyndaqel/Vyndamax (tafamidis), and Norvasc (amlodipine); primary care products such as Zavzpret (zavegepant), Chantix (varenicline), and Litfulo (ritlecitinib); antivirals like Paxlovid (nirmatrelvir/ritonavir); and consumer brands including Advil, ChapStick, and Robitussin. Founded in 1849 by Charles Pfizer and Charles F. Erhart and headquartered at 235 East 42nd Street in Manhattan, New York City, Pfizer operates manufacturing and research facilities globally across North America, Europe, Asia, and Latin America, serving healthcare providers, governments, and patients in over 100 countries. In recent developments, Pfizer completed the acquisition of Metsera in November 2025 for an initial enterprise value of $4.9 billion plus a contingent value right, adding clinical-stage obesity and cardiometabolic candidates including oral and injectable incretins; new products and acquired launches contributed $7.3 billion in incremental revenue through Q3 2025; and the company plans $10-15 billion in business development investments for 2025, emphasizing early-stage assets and collaborations, particularly with Chinese biotechs via its Ignite platform.
Company News
How To Earn $500 A Month From Pfizer Stock Ahead Of Q3 Earnings
Hedge Your Retirement Income With These 2 Cash-Generating Picks
Pfizer Just Hit a 52-Week High. Is the Turnaround Finally Real?
$250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in Dividends
Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
Pfizer: Reality Check Ahead Of Earnings
Pfizer Yields Nearly 6%, but Its Dividend Exceeds Free Cash Flow. Is It Safe?
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?
Edison Scientific Announces Agreement with Pfizer to Accelerate Research and Development
Exploring Analyst Estimates for Pfizer (PFE) Q3 Earnings, Beyond Revenue and EPS
Are Your Dividends Safe? 4 Yields That Are High for the Wrong Reason
Obesity Pipeline vs. COVID Drag: The Hidden Numbers Deciding Pfizer's Q3 Fate on Nov. 3
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why
Pfizer Stock Ahead of Q3 Earnings: To Buy or Not to Buy?
3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now
Pfizer Cancer Therapy Shows Extended Progression-Free Survival in Multiple Myeloma Patients
$200,000 in Dividend Stocks: How Much More Could You Keep in a Roth IRA?
Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?
3 Dirt Cheap Dividend Stocks to Buy Hand Over Fist
Pfizer's ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma